Virologic (NASDAQ:VLGC)
Historical Stock Chart
From Aug 2019 to Aug 2024
ViroLogic to Present at the First Annual Merriman Curhan Ford &
Co. Investor Summit on September 20, 2004
SOUTH SAN FRANCISCO, Calif., Sept. 13 /PRNewswire-FirstCall/ -- ViroLogic,
Inc. (NASDAQ:VLGC) announced today that Bill Young, CEO and Chairman of
ViroLogic, is scheduled to present a corporate overview at the first annual
Merriman Curhan Ford & Co. Investor Summit on Monday, September 20, 2004 at
8:30 a.m. This event will be held at the Mark Hopkins Inter-Continental Hotel
in San Francisco.
To access the live audio broadcast, or the subsequent archived recording, log
on to the investor relations section of the Company's website at
http://www.virologic.com/ . The archived version of the webcast will be
available on the Company's website for one month.
About ViroLogic
ViroLogic is a biotechnology company advancing individualized medicine by
discovering, developing and marketing innovative products to guide and improve
treatment of serious viral diseases such as AIDS and hepatitis. The Company's
products are designed to help doctors optimize treatment regimens that lead to
better patient outcomes and reduced costs. ViroLogic's technology is also being
used by numerous biopharmaceutical companies to develop new and improved
anti-viral therapeutics and vaccines targeted at emerging drug-resistant
viruses. More information about the Company and its technology can be found on
its website at http://www.virologic.com/.
Certain statements in this press release are forward-looking. These
forward-looking statements are subject to risks and uncertainties and other
factors, which may cause actual results to differ materially from the
anticipated results or other expectations expressed in such forward-looking
statements. These risks and uncertainties include, but are not limited to, the
timing of pharmaceutical company clinical trials, risks related to our pending
merger with ACLARA BioSciences, Inc. (ACLARA), including the risk that the
closing conditions of the merger may not be satisfied and the merger may not be
completed, and costs related to the proposed merger may adversely impact
ViroLogic's financial performance, the risks that the Company's products may
not perform, whether ViroLogic successfully introduces new products, risks
related to the implementation of the Company's distribution agreement with a
major national laboratory, whether others introduce competitive products, the
risk that the Company's products for patient testing may not continue to be
accepted or that increased demand from drug development partners may not
develop as anticipated, the risk that gross margins may not increase as
expected, whether payors will authorize reimbursement for its products, whether
the FDA or any other agency will decide to regulate ViroLogic's products or
services, whether the Company will encounter problems or delays in automating
its processes, whether intellectual property underlying the Company's
PhenoSense(TM) technology is adequate, whether licenses to third party
technology will be available, whether ViroLogic is able to build brand loyalty
and expand revenues, and whether ViroLogic will be able to raise sufficient
capital when required. For a discussion of other factors that may cause
ViroLogic's actual events to differ from those projected, please refer to the
Company's most recent annual report on Form 10-K, quarterly reports on Form
10-Q, and the preliminary Joint Proxy/Prospectus related to the proposed merger
with ACLARA, as well as other subsequent filings with the Securities and
Exchange Commission.
DATASOURCE: ViroLogic, Inc.
CONTACT: Karen Wilson, CFO of ViroLogic, Inc., +1-650-624-4164, or
Web site: http://www.virologic.com/